Entertainment: Starting as a Succubus, Taking Hollywood by Storm

Why was Martin so keen on connecting with Elbit Systems' top executives in the U.S. and, through them, reaching the core members of Israel's Weizmann Institute of Science? Simple: if he could get close to them, he could turn them into his allies. These were, after all, some of the smartest people on the planet.

Martin was scheming to poach talent from Elbit Systems and the Weizmann Institute. Just how formidable were these organizations?

Elbit Systems and the Weizmann Institute are two sides of the same coin, deeply intertwined. The Weizmann Institute, originally the Daniel Sieff Research Institute founded in 1934, was led by Professor Chaim Weizmann, who later became Israel's first president. Though modest in size with just over 2,000 researchers, the institute boasts top-tier talent in mathematics, computer science, physics, chemistry, and biology.

Elbit Systems, Israel's leading tech commercialization company, is one of the world's most successful in its field. It inherited the Weizmann Institute's ethos of prioritizing research and patents, focusing on turning scientific breakthroughs into profit. Their motto? "Let scientists focus on research; we'll handle the rest."

Honestly, [U.S,] could learn a thing or two from Elbit's approach, especially its scientist incentive system. Elbit employs four key mechanisms:

Direct Investment: Elbit's internal financing arm funds Weizmann Institute research, ensuring smooth progress while securing intellectual property rights from the outset.

Government Grants: Elbit and the Weizmann Institute jointly apply for government projects, receiving subsidies covering 66% to 90% of costs. Patents remain with the research institution, but usage rights are licensed to the company.

Reward Funds: When Weizmann labs publish cutting-edge research, Elbit offers financial rewards.

Profit Sharing: Elbit shares commercialization profits with investors and researchers, with 40% of tech transfer revenue going directly to individual scientists, not their labs.

This creates a powerful incentive: successful commercialization means Elbit profits, and scientists can become fabulously wealthy. It's a win-win, chaining researchers to Elbit's chariot while scaling the company's success. The terms are set in advance and strictly followed—a masterclass in business from the Jewish playbook.

How strong is Elbit? It's the only company globally holding patents for three of the world's most profitable drugs, each generating over $1 billion annually.

Martin coveted Elbit's elite managers but was even more eager for their scientists. In his vision for Guinea's future, the upper echelons would be dominated by asian and white populations, with Black people filling repetitive, mechanical roles at the bottom. That said, he'd gladly elevate any Black geniuses to the upper ranks. It was a classic "pyramid society" structure—stable and enduring.

...

At Disney's boardroom, a vote was underway.

"I abstain," one director said.

"I support the acquisition proposal," another chimed in.

Edward Disney, Roy Disney's son, scoffed. "How can you back someone like him? Robert Iger should resign from all his Disney roles."

Iger smirked coldly. "You and your father know exactly where those negative rumors came from. No one here's a fool. We all know who's reckless and who can take Disney to greater heights."

Lucasfilm, valued at over $4 billion, wasn't something Disney could acquire overnight. Even raising the funds would take time.

"What?" Edward sputtered.

"What the fuck!" Roy Disney exclaimed.

Iger stared them down, his expression unchanging.